Abstract: A method for the prevention or reduction of sensitization to a pharmaceutical drug for Parkinson's disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. A method for the optimization of the dosage of a pharmaceutical drug for Parkinson's disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.

Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Abstract: Provided is a method of treating patients with cluster headache comprising intranasal administration to a patient in need thereof of an aqueous composition, e.g., pharmaceutical composition, comprising a therapeutically effective amount of ketamine, a method of reducing or eliminating side effects of ketamine when used in the treatment of Cluster headache, and to a composition, e.g., pharmaceutical composition, comprising a therapeutically effective amount of ketamine for use in the treatment of cluster headache, wherein the composition is in a nasal dosage form such as a nasal spray.

Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Abstract: Provided is a method of treating patients with Cluster Headache (CH) including chronic Cluster Headache (cCH) comprising intranasal administration to a patient in need thereof of an aqueous composition, e.g., pharmaceutical composition, comprising a therapeutically effective amount of ketamine, which may reduce or eliminate side effects of ketamine when used in the treatment of Cluster Headache, and to a composition, e.g., pharmaceutical composition, comprising a therapeutically effective amount of ketamine for use in the treatment of Cluster Headache, wherein the composition is in a nasal dosage form such as a nasal spray.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: The present invention relates to an electrostatic precipitator (ESP) system (1) for removal of particles from a flue gas flowing in a flow passage (4) being delimited by a primary collection in the form of a collection plate (5). The system comprises a discharge electrode (11) arranged in the flow passage and connected to a high voltage generator (12) providing for an electric field around the discharge electrode. The system further has a secondary collection electrode in the form of a grid (101) arranged within the collection plate and made of an electrically conductive material. The presence of such a grid improves the efficiency of the precipitator. In some embodiments, the ESP system comprises an actuator (112) for moving the grid upwards and letting it drop onto an internal bottom structure (109). The movement between the collection plate and the grid as well as the impact force imparted to the dropping grid both result in a removal of collected particles.

Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It also provides improved pharmacokinetic parameters due to an extended and constant in vivo release including substantial decreased peak concentrations, despite increased bioavailability, substantial extended times for maximal concentration, and higher minimal concentrations when compared with conventional immediate release dosage forms and a recent modified release tacrolimus dosage form.

Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.

Abstract: Holder for a rotary tool which holder is formed with a holder body comprising a rear drive end and a front connection end having a connection thread for the connection of the tool. The holder comprises a thrust collar having a flat contact surface facing a connection end of the holder. The holder comprises an axially movable operating means, a number of restraint elements placed in one or more spaces in the holder body which restraint elements in a first axial position of the operating means are prevented from radial movement in said spaces and which restraint elements in a second axial position of the operating means allow radial movement in said spaces. Each one of said spaces for the restraint elements is limited in the axial direction by a front limiting wall and a rear limiting wall, which two limiting walls are parts of the holder body.

Abstract: A pharmaceutical composition comprising tacrolimus (FK-506) dissolved and/or dispersed in a hydrophilic or water-miscible vehicle to form a solid dispersion or solid solution at ambient temperature have improved bioavailability.

Abstract: The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Abstract: The present invention relates to an electrostatic precipitator (ESP) system (1) for removal of particles from a flue gas flowing in a flow passage (4) being delimited by a primary collection in the form of a collection plate (5). The system comprises a discharge electrode (11) arranged in the flow passage and connected to a high voltage generator (12) providing for an electric field around the discharge electrode. The system further has a secondary collection electrode in the form of a grid (101) arranged within the collection plate and made of an electrically conductive material. The presence of such a grid improves the efficiency of the precipitator. In some embodiments, the ESP system comprises an actuator (112) for moving the grid upwards and letting it drop onto an internal bottom structure (109). The movement between the collection plate and the grid as well as the impact force imparted to the dropping grid both result in a removal of collected particles.

Abstract: Holder for a rotary tool which holder is formed with a holder body comprising a rear drive end and a front connection end having a connection thread for the connection of the tool. The holder comprises a thrust collar having a flat contact surface facing a connection end of the holder. The holder comprises an axially movable operating means, a number of restraint elements placed in one or more spaces in the holder body which restraint elements in a first axial position of the operating means are prevented from radial movement in said spaces and which restraint elements in a second axial position of the operating means allow radial movement in said spaces. Each one of said spaces for the restraint elements is limited in the axial direction by a front limiting wall and a rear limiting wall, which two limiting walls are parts of the holder body.